Ginkgo Bioworks Holdings Analyst Ratings
Ginkgo Bioworks Holdings Analyst Ratings
While ratings are subjective and will change, the latest Ginkgo Bioworks Holdings (DNA) rating was a downgraded with a price target of $0.00 to $2.50. The current price Ginkgo Bioworks Holdings (DNA) is trading at is $1.37, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 83.15% | Raymond James | → $2.5 | Downgrades | Outperform → Market Perform |
| 11/09/2023 | — | BTIG | Downgrades | Buy → Neutral | |
| 06/05/2023 | -8.42% | Goldman Sachs | $3 → $1.25 | Maintains | Sell |
| 06/02/2023 | -8.42% | Goldman Sachs | $3 → $1.25 | Downgrades | Neutral → Sell |
| 05/11/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 11/29/2022 | 339.56% | Berenberg | → $6 | Initiates Coverage On | → Buy |
| 10/04/2022 | 266.3% | Morgan Stanley | → $5 | Initiates Coverage On | → Equal-Weight |
| 08/16/2022 | 339.56% | BTIG | $5 → $6 | Maintains | Buy |
| 08/16/2022 | 962.27% | Raymond James | $11.5 → $14.5 | Maintains | Outperform |
| 06/16/2022 | 218.68% | Jefferies | $11.5 → $4.35 | Maintains | Buy |
| 05/18/2022 | 119.78% | B of A Securities | $6 → $3 | Downgrades | Neutral → Underperform |
| 03/02/2022 | 779.12% | Cowen & Co. | → $12 | Initiates Coverage On | → Outperform |
| 02/23/2022 | 412.82% | Goldman Sachs | → $7 | Initiates Coverage On | → Neutral |
| 02/01/2022 | 339.56% | B of A Securities | → $6 | Initiates Coverage On | → Neutral |
| 01/28/2022 | 486.08% | B of A Securities | → $8 | Initiates Coverage On | → Buy |
| 01/07/2022 | 779.12% | BTIG | → $12 | Initiates Coverage On | → Buy |
| 10/13/2021 | 962.27% | Raymond James | → $14.5 | Initiates Coverage On | → Outperform |
| 10/12/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 09/20/2021 | 925.64% | HSBC | → $14 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/14/2023 | 83.15% | 雷蒙德·詹姆 | → 2.5 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 11/09/2023 | — | BTIG | 降級 | 買入 → 中性 | |
| 06/05/2023 | -8.42% | 高盛 | 3 美元 → 1.25 美元 | 維護 | 賣出 |
| 06/02/2023 | -8.42% | 高盛 | 3 美元 → 1.25 美元 | 降級 | 中性 → 賣出 |
| 05/11/2023 | — | 威廉布萊爾 | 降級 | 跑贏大盤 → 市場表現 | |
| 2022 年 11 月 29 日 | 339.56% | 貝倫貝格 | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 4 月 10 日 | 266.3% | 摩根士丹利 | → 5 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 08/16/2022 | 339.56% | BTIG | 5 美元 → 6 美元 | 維護 | 買 |
| 08/16/2022 | 962.27% | 雷蒙德·詹姆 | 11.5 美元 → 14.5 美元 | 維護 | 跑贏大盤 |
| 06/16/2022 | 218.68% | 傑富瑞集團 | 11.5 美元 → 4.35 美元 | 維護 | 買 |
| 05/18/2022 | 119.78% | B of A 類證券 | 6 美元 → 3 美元 | 降級 | 中性 → 跑贏大盤 |
| 03/02/2022 | 779.12% | Cowen & Co. | → 12 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2022 年 2 月 23 日 | 412.82% | 高盛 | → 7 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 2022 年 1 月 2 日 | 339.56% | B of A 類證券 | → 6 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 01/28/2022 | 486.08% | B of A 類證券 | → 8 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 7 月 1 日 | 779.12% | BTIG | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 10 月 13 日 | 962.27% | 雷蒙德·詹姆 | → 14.5 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 12 月 10 日 | — | 威廉布萊爾 | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 09/20/2021 | 925.64% | 匯豐銀行 | → 14 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Ginkgo Bioworks Holdings (DNA)?
銀杏生物工程控股公司（DNA）的目標價格是多少？
The latest price target for Ginkgo Bioworks Holdings (NYSE: DNA) was reported by Raymond James on November 14, 2023. The analyst firm set a price target for $2.50 expecting DNA to rise to within 12 months (a possible 83.15% upside). 6 analyst firms have reported ratings in the last year.
雷蒙德·詹姆斯於2023年11月14日公佈了銀杏生物工程控股公司（紐約證券交易所代碼：DNA）的最新目標股價。該分析公司將目標股價定爲2.50美元，預計DNA將在12個月內升至12個月內（可能上漲83.15％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Ginkgo Bioworks Holdings (DNA)?
Ginkgo Bioworks Holdings（DNA）的最新分析師評級是多少？
The latest analyst rating for Ginkgo Bioworks Holdings (NYSE: DNA) was provided by Raymond James, and Ginkgo Bioworks Holdings downgraded their market perform rating.
雷蒙德·詹姆斯對銀杏生物工程控股公司（紐約證券交易所代碼：DNA）的最新分析師評級由雷蒙德·詹姆斯提供，銀杏生物工程控股下調了其市場表現評級。
When is the next analyst rating going to be posted or updated for Ginkgo Bioworks Holdings (DNA)?
Ginkgo Bioworks Holdings（DNA）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ginkgo Bioworks Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ginkgo Bioworks Holdings was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Ginkgo Bioworks Holdings的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Ginkgo Bioworks Holdings的最新評級是在2023年11月14日公佈的，因此您應該預計下一個評級將在2024年11月14日左右公佈。
Is the Analyst Rating Ginkgo Bioworks Holdings (DNA) correct?
分析師對銀杏生物工程控股公司（DNA）的評級是否正確？
While ratings are subjective and will change, the latest Ginkgo Bioworks Holdings (DNA) rating was a downgraded with a price target of $0.00 to $2.50. The current price Ginkgo Bioworks Holdings (DNA) is trading at is $1.37, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Ginkgo Bioworks Holdings（DNA）評級已下調，目標股價爲0.00美元，至2.50美元。銀杏生物工程控股公司（DNA）目前的交易價格爲1.37美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。